All News

A new study suggests that even though the profession is at a crossroads, the path toward improvement depends heavily on the setting in which a pharmacist practices.

Gretchen Garofoli, PharmD, BCACP, CTTS, FAPhA, provides her perspective on the back-and-forth stemming from the federal government regarding US vaccine guidelines.

New Glycemia Risk Index data shows continuous glucose monitoring cuts hypo- and hyperglycemia risk in type 1 diabetes, giving pharmacists a faster way to estimate control.

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, dives deeper into recent comments from the FDA commissioner and what they mean for OTC medication access.

New study links basal‑prandial insulin to healthier remnant cholesterol in type 2 diabetes, spotlighting hidden cardiovascular risk beyond low-density lipoprotein and A1c.

With efforts to further scale naloxone access in US community pharmacies, researchers explore the implementation of a hub-and-spoke distribution model.

Lilly’s once-weekly retatrutide lowers A1C up to 2% and drives nearly 17% weight loss in type 2 diabetes, signaling a powerful triple-agonist shift.

Along with presenting best practices for pharmacies’ vaccination workflows, researchers explore the impact of community pharmacies offering technician-administered vaccines.

With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden.

MAHA-driven HHS shifts vaccines and nutrition, fueling public health debate as pharmacists battle social media misinformation and rebuild trust.

The FDA clears the highest-dose weekly semaglutide for obesity, showing 20.7% mean weight loss with the same blood sugar-lowering effects.

Pharmacists help women with type 1 diabetes plan pregnancy, adjust insulin and tech, and stay safe postpartum with personalized guidance.

In Texas community pharmacies, researchers assess the communication concordance between pharmacists and patients during medication counseling.

MiniMed Flex is a smaller, screenless, and phone-controlled insulin automation that shows how pharmacists boost AID success for patients with diabetes.

Annie Lambert, PharmD, BCSCP, discusses pharmacies’ regulation and compliance needs when it comes to dispensing compounded GLP-1s.

The new parameter combines waist circumference, hypertension status, and glycated hemoglobin to determine insulin resistance.

FDA approves icotrokinra as a first-line systemic treatment of plaque psoriasis with a targeted oral peptide for adults and pediatric patients.

Investigators used a large cohort of patients from Taiwan between 2004 and 2015 to determine the potential link between Tylenol use and childhood neurodevelopment.

Combined with nutritional interventions, semaglutide also demonstrates greater weight loss compared with dulaglutide.

CDC researchers investigate pneumococcal disease cases and intervention strategies within a North Carolina correctional facility from June 14 to July 30, 2024.

The health care landscape for metabolic liver disease is undergoing a shift, and pharmacists are being positioned at the forefront of this therapeutic revolution.

The FDA clears secukinumab for patients 12 years and older with tough hidradenitis suppurativa, offering weight-based IL‑17A biologic relief and new guidance on screening and safety.

From patient perspectives on acceptability, researchers assess the impact of pharmacist-led point-of-care testing services in rural Tennessee communities.

Remote hub model in New Zealand upskills pharmacists to launch automated insulin delivery faster, expanding equitable access for type 1 diabetes.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.

Eli Lilly flags unknown impurities in compounded tirzepatide with B12 as FDA targets misleading GLP-1 marketing.